Wyoming Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• ACC Leaders Engage With Key Senators During Annual House Call on the Mall Event
  ACC President Christopher M. Kramer, MD, FACC, and HeartPAC Vice Chair Andrew R. Waxler, MD, FACC, met with several senators during this year’s House Call on the Mall...
• ACC, Smith Center to Collaborate to Advance Renal Denervation Knowledge
  In an effort to expand the collection of real-world data on patients undergoing renal denervation (RDN) across hospitals in the U.S., the ACC and the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center (BIDMC) are collaborating on an RDN module that leverages the ACC's CathPCI Registry and […]
• Long-Term Outcomes of Patients With TR Undergoing MViV Replacement | NCDR Study
  Patients undergoing transseptal mitral valve-in-valve (MViV) replacement with preprocedural severe or greater tricuspid regurgitation (TR), 30-day residual severe or greater TR, and unchanged or worsened TR post procedure, had a greater risk of all-cause mortality at the three-year follow-up...
• Lower Risk of Major Adverse Events, Ischemic Stroke in LAAO With Watchman FLX | NCDR Study
  Patients undergoing transcatheter left atrial appendage occlusion (LAAO) with the Watchman FLX had significantly lower risk of major adverse events and ischemic stroke at one year vs. patients implanted with the Watchman 2.5 device...
• ACCEL Lite: Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation
  In this episode, Drs. Allen J. Taylor and Sergio Raposeiras Roubin discuss the safety and clinical benefits of initiating dapagliflozin—or other SGLT-2 inhibitors—in patients undergoing TAVI who are at risk for heart failure, emphasizing its potential to improve outcomes in this high-risk population.